---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059659"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:08:59.414533+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Novavax signs $1.3B Sanofi deal; Q1 revenue $94M, net loss $148M; removes going concern

## Summary
- Co-exclusive licensing with Sanofi includes $500M upfront, ~$70M equity, up to $700M milestones plus royalties per product.
- Q1 2024 revenue $94M (up from $81M YoY), net loss $148M (improved from $294M loss YoY).
- Reduced current liabilities by $831M in Q1; removed going concern notice.
- Updated 2024 guidance: Combined Revenue & Sanofi Payments $970M-$1,170M; Total Revenue $400M-$600M.
- Added standalone influenza arm to Phase 3 COVID-Flu combo trial; on track for H2 2024 initiation, potential 2026 launch.

## SEC filing metadata
- accession: 0001104659-24-059659
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/0001104659-24-059659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/tm2414089d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059659
- JSON: https://secwatch.observer/filing/0001104659-24-059659.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059659.txt

## Key facts
- Earnings Releases
  NOVAVAX INC reported the first quarter ended March 31, 2024 results: revenue $94 million.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $94 million
  - Result: reported results
  source text: half of 2024, with potential 2026 launch for both candidates · Reduced current liabilities by an additional $831 million during Q1 2024 · Achieved total revenue in Q1 2024 of $94 million · Novavax removes going concern notice · Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md., May 10, 2024 – Novavax, Inc. (Nasdaq: NVAX), a global company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/0001104659-24-059659-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.